SINGAPORE — July 25, 2018 — PharmaJet® the maker of innovative, needle-free injection technology, and Mundipharma, today announced an exclusive partnership for the multinational healthcare organization to market and distribute PharmaJet’s Tropis® and Stratis® needle-free devices across more than 120 markets worldwide.
Tropis® (ID) and Stratis® (IM/SC) devices are both optimized for vaccine immunizations. The Tropis® device has been shown in multiple studies to deliver a superior immune response after 2 fIPV , doses and uniquely enables mass-scale fractional dose poliovirus vaccine injections at a lower total cost than intramuscular injection . PharmaJet has a multi-year agreement with the World Health Organization (WHO) to provide its Needle-free technology for use in the global effort to eradicate polio.
With a vertically integrated R&D-to-distribution pipeline, Mundipharma has a strong track record of building successful alliances with industry partners to license, market and distribute solutions that improve patients’ lives, while also providing options for financially constrained healthcare systems.
Mundipharma CEO, Raman Singh, said, “The aim of this partnership is to provide access to this unique needle-free injection technology, to more patients – particularly in the emerging world where outbreaks typically occur, and availability and cost can be a barrier to vaccinations. This includes addressing the shortage-driven need for easy-to-use, fractional dose Inactivated Poliovirus Vaccine (fIPV) intradermal delivery systems. Distributing PharmaJet’s needle-free technology aligns well with our aim to provide access to innovative, cost-effective, and safe solutions for the healthcare providers and patients who need it the most.”
“Mundipharma’s global network provides the commercial expertise to broaden and accelerate our expansion of needle-free devices within emerging markets,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc. “We look forward to working together to drive our efforts with health ministries to improve Polio, MMR and influenza vaccinations across the emerging world.”
Healthios Capital Markets LLC (“Healthios”), a US life sciences investment banking boutique, advised PharmaJet on the distribution agreement with Mundipharma. The distribution agreement supports PharmaJet’s private-to-public financing pathway in Singapore. Among its services Healthios advises clients on placements of convertible securities conditioned upon an initial public offering on the Singapore Exchange with a pathway back to a cross-listing on Nasdaq.
Refer to Instructions for Use to ensure safe injections and to review risks.
®: TROPIS and STRATIS are Registered Trademarks in the US and Registered Trademarks in other countries, of PharmaJet.
1 Clarke et al. Lancet Glob Health 2016; 4:e534-47.
2 Resik et al. Vaccine 2015; 33:307-313.
3 Mohammad Tahir Yousafzai et al. Heliyon 3 (2017) e00395.
4 Weniger BG, Papania MJ. Alternative Vaccine Delivery Methods (Chapter 61). In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 6th ed. Philadelphia: Elsevier / Saunders; 2013, pp. 1200-1231.
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
For more information please visit: www.mundipharma.com.sg
Chief Communications Officer & Head, Digital Strategy –
Asia Pacific, Latin America the Middle East & Africa
+65-6303-9732 | firstname.lastname@example.org